Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents

References

• WarrenJLYabroffKRMeekinsAToporMLamontEBBrownMLEvaluation of trends in the cost of initial cancer treatmentJ Natl Cancer Inst200810088889718544740
   PubMed Web of Science ®Google Scholar
• MariottoABYabroffKRShaoYFeuerEJBrownMLProjections of the cost of cancer care in the United States: 2010–2020J Natl Cancer Inst201110311712821228314
   PubMed Web of Science ®Google Scholar
• VergnenègreAChouaidCAspects médico-économiques de la pneumologie [Economic aspects of respiratory disease management]Rev Mal Resp20124196207
   Google Scholar
• CiprianoLERomanusDEarleCCLung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003Value Health201114415221211485
   PubMed Web of Science ®Google Scholar
• CoateLELeighlNBHow affordable are targeted therapies in non-small cell lung cancer?Curr Treat Options Oncol20111211121267683
   PubMed Web of Science ®Google Scholar
• ChouaidCAtsouKHejblumGVergnenègreAEconomics of treatments for non-small cell lung cancerPharmacoeconomics20092711312519254045
   PubMed Web of Science ®Google Scholar
• ChouaidCMonnetIRobinetGPerolMFournelPVergnenègreAEconomic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysisCurr Med Res Opin2007231509151517559745
   PubMed Web of Science ®Google Scholar
• ThongprasertSTinmaneeSPermsuwanUCost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspectiveAsia Pac J Clin Oncol20128536122369444
   PubMed Web of Science ®Google Scholar
• HorganAMBradburyPAAmirEAn economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancerAnn Oncol2011221805181121273345
   PubMed Web of Science ®Google Scholar
• BrownTBolandABagustAGefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2717921047494
   PubMed Web of Science ®Google Scholar
• de Lima LopesGJrSegelJETanDSDoYKMokTFinkelsteinEACost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lungCancer20121181032103921792863
   PubMed Web of Science ®Google Scholar
• BorgetICadranelJPignonJPCost-effectiveness of three strategies for second-line erlotinib initiation in non-small-cell lung cancer: the ERMETIC study part 3Eur Respir J20123917217921659409
   PubMed Web of Science ®Google Scholar
• ChouaidCMoserACoudray-OmnesCVergnenègreAConséquences economiques de l’erlotinib dans le traitement des cancers bronchopulmonaires non à petites cellules [The economic consequences of erlotinib in the treatment of non-small-cell broncho-pulmonary cancer]Rev Mal Respir20082510961103 French19106905
   PubMed Web of Science ®Google Scholar
• IslaDGonzalez-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol20111346047121775273
   PubMed Web of Science ®Google Scholar
• BradburyPATuDSeymourLEconomic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancerJ Natl Cancer Inst201010229830620160168
   PubMed Web of Science ®Google Scholar
• LeighlNBTsaoWSZawiszaDLNematollahiMShepherdFAA willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancerLung Cancer20065111512116188343
   PubMed Web of Science ®Google Scholar
• LangHCWillingness to pay for lung cancer treatmentValue Health20101374374920561327
   PubMed Web of Science ®Google Scholar
• CarlsonJJReyesCOestreicherNLubeckDRamseySDVeenstraDLComparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)Lung Cancer20086140541518295368
   PubMed Web of Science ®Google Scholar
• LewisGPeakeMAultmanRCost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United KingdomJ Int Med Res20103892120233509
   PubMed Web of Science ®Google Scholar
• Doral StefaniSGiorgio SaggiaMVicino dos SantosEACost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspectiveJ Med Econ20081138339619450094
   PubMedGoogle Scholar
• McLeodCBagustABolandAErlotinib for the treatment of relapsed non-small cell lung cancerHealth Technol Assess200913Suppl 1414719567213
   PubMed Web of Science ®Google Scholar
• SchwanderBRaveraSGiulianiGNuijtenMWalzerSCost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for ItalyClinicoecon Outcomes Res2012423724322969300
   PubMedGoogle Scholar
• CromwellIvan der HoekKMeloskyBPeacockSErlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysisJ Thorac Oncol201162097210322052223
   PubMed Web of Science ®Google Scholar
• CromwellIvan der HoekKMalfair TaylorSCMeloskyBPeacockSErlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysisLung Cancer20127647247722226627
   PubMed Web of Science ®Google Scholar
• BongersMLCoupeVMJansmaEPSmitEFUyl-de GrootCACost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic reviewPharmacoeconomics201230173422201521
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol20101152152920493771
   PubMed Web of Science ®Google Scholar
• NuijtenMJde Castro CarpeñoJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer20127646547122153602
   PubMed Web of Science ®Google Scholar
• DicksonRBagustABolandAErlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalPharmacoeconomics2011291051106221967156
   PubMed Web of Science ®Google Scholar
• VergnenègreARayJAChouaidCCross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerClinicoecon Outcomes Res20124313722347803
   PubMedGoogle Scholar
• CarlsonJJGarrisonLPRamseySDVeenstraDLThe potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancerValue Health200912202718647257
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• NuijtenMHeigenerDFBischoffHGEffectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerLung Cancer201069Suppl 1S4S1020727460
   PubMedGoogle Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• ChienCRShihYCEconomic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)Clinicoecon Outcomes Res2012420120822870040
   PubMedGoogle Scholar
• GiulianiGGrossiFde MarinisFWalzerSCost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in ItalyLung Cancer201069Suppl 1S11S1720727457
   PubMedGoogle Scholar
• AhnMJTsaiCMHsiaTCCost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and TaiwanAsia Pac J Clin Oncol20117223321585705
   PubMed Web of Science ®Google Scholar
• StanisicSBischoffHGHeigenerDFSocietal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Lung Cancer201069Suppl 1S24S3020727459
   PubMedGoogle Scholar